Sound Shore Management Inc. CT Sells 46,739 Shares of Hologic, Inc. (NASDAQ:HOLX)

Sound Shore Management Inc. CT lowered its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 4.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 970,225 shares of the medical equipment provider's stock after selling 46,739 shares during the quarter. Hologic accounts for approximately 2.3% of Sound Shore Management Inc. CT's portfolio, making the stock its 24th largest position. Sound Shore Management Inc. CT owned approximately 0.43% of Hologic worth $69,944,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. General Partner Inc. bought a new stake in Hologic in the fourth quarter valued at $26,000. Venturi Wealth Management LLC increased its position in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 134 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HOLX. Royal Bank of Canada dropped their price objective on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 6th. Jefferies Financial Group initiated coverage on Hologic in a research report on Tuesday, December 10th. They set a "hold" rating and a $85.00 price target for the company. Needham & Company LLC lowered shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective on the stock. in a research report on Monday, February 3rd. Citigroup dropped their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Finally, Morgan Stanley lowered their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $84.62.

Hologic Price Performance

Shares of Hologic stock traded down $1.00 during trading on Friday, hitting $61.32. 1,110,999 shares of the stock traded hands, compared to its average volume of 1,809,690. The stock has a market cap of $13.76 billion, a price-to-earnings ratio of 19.34, a PEG ratio of 2.14 and a beta of 0.97. The firm's fifty day moving average is $65.24 and its 200-day moving average is $73.35. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52 week low of $60.34 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.